Is This Dividend Growth Stock a Buy?

Concerns about inflation -- and now, a possible recession -- have led the S&P 500 index to drop 17% so far this year. But some stocks have fared much better than the broader market.

The pharma stock Eli Lilly (NYSE: LLY) has surged 13% higher year to date. But has the stock's rally made it too expensive? Let's dive into Eli Lilly's fundamentals and valuation to find out.

Eli Lilly reported $7.8 billion in revenue for the first quarter ended March 31, up 14.8% from the year-ago period. How did the large-cap company deliver double-digit revenue growth to its shareholders in the first quarter?

Source Fool.com